PYPD vs ACRS vs NKTR vs ABBV

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -98. 3% for PolyPid Ltd. (PYPD). Over 10 years, the gap is even starker: ABBV returned +293. 8% versus PYPD's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.

(ACRS) is the lower-risk stock at 0. 22β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 720% more volatile than ACRS relative to the S&P 500. On balance sheet safety, PolyPid Ltd. (PYPD) carries a lower debt/equity ratio of 25% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus -58. 2% for Aclaris Therapeutics, Inc. (ACRS). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ABBV leads at 1. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACRS: 118.

1% to $10. 60.

In this comparison, ABBV (3.

2% yield) pays a dividend. PYPD, ACRS, NKTR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 2% yield, +293. 8% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +293. 8%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PYPD is a small-cap quality compounder stock; ACRS is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while PYPD, ACRS, NKTR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.